Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 13/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 12/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4693377 | 1.00 | DPP4 (0.53) | DPP4DPP7DPP9DPP8RIPK1 | |
| SCHEMBL4693374 | 1.00 | DPP4 (0.53) | DPP4DPP7DPP9DPP8RIPK1 | |
| Hydrochloric Acid SCHEMBL496559 | 0.99 | DPP4 (0.52) | DPP4DPP7DPP9DPP8RIPK1 | |
| SCHEMBL496083 | 0.78 | RIPK1 (0.41) | DPP4DPP7DPP9DPP8RIPK1 | |
| SCHEMBL496081 | 0.78 | RIPK1 (0.41) | DPP4DPP7DPP9DPP8RIPK1 | |
| SCHEMBL5106607 | 0.72 | CSNK1E (0.49) | — | |
| Hydrochloric Acid SCHEMBL497143 | 0.71 | CSNK1E (0.48) | — | |
| SCHEMBL269523 | 0.69 | DPP4 (0.47) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL4119170 | 0.69 | MAPT (0.39) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL269091 | 0.69 | MAPT (0.39) | DPP4DPP7DPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910317-B1 | 1-AMINO LINKED COMPOUNDS | LILLY CO ELI (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8106090-B2 | Antidiabetic agents; prevent of non-insulin dependent diabetes | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106090-B2 | Antidiabetic agents; prevent of non-insulin dependent diabetes | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106090-B2 | Antidiabetic agents; prevent of non-insulin dependent diabetes | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-20080207735-A1 | 1-Amino Linked Compounds | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207735-A1 | 1-Amino Linked Compounds | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207735-A1 | 1-Amino Linked Compounds | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| WO-2007015805-A1 | 1-AMINO LINKED COMPOUNDS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207735-A1 | 1-Amino Linked Compounds | DPP4, DPP3, DPP9 | DPP4 1/4885DPP7 6/4885DPP9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.